Erratum: Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding (Leukemia (2012) 26 (1338-1347) DOI: 10.1038/leu.2011.331);Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding

Leukemia

Volumn 26, Issue 6, 2012, Pages 1338-1347

  Seshire, A ^a   Robiger T ^b   Frech, M ^b   Beez, S ^b   Hagemeyer, H ^b   Puccetti, E ^b  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

AML; interaction; phosphorylation; PU.1 SPI1

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SERINE; TRANSCRIPTION FACTOR PU 1;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

EID: 84862000583     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.170     Document Type: Erratum

References (53)

1. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARαl and the leukemic stem cell. Leukemia 2004; 18: 1169-1175. (Pubitemid 39023127)
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064. (Pubitemid 27517875)
3. Melnick A, Licht JD. Deconstructing a disease: RARαl, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215. (Pubitemid 29220886)
4. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG et al. A PMLRARαl transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 2551-2556. (Pubitemid 27136913)
5. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 1997; 89: 376-387. (Pubitemid 27051671)
6. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V et al. Acute leukemia with promyelocytic features in PML/RARαl transgenic mice. Proc Natl Acad Sci USA 1997; 94: 5302-5307. (Pubitemid 27214778)
7. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191. (Pubitemid 28533038)
8. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia. Nature 1998; 391: 815-818. (Pubitemid 28099683)
9. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2003; 101: 270-277. (Pubitemid 36025918)
10. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002; 62: 7050-7058. (Pubitemid 35424100)
11. Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. Role of transcription factors C/EBPalpha and PU1 in normal hematopoiesis and leukemia. Int J Hematol 2005; 81: 368-377. (Pubitemid 40921745)
12. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197. (Pubitemid 30154488)
13. Miyamoto T, Iwasaki H, Reizis B, Ye M, Graf T, Weissman IL et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell 2002; 3: 137-147. (Pubitemid 34778402)
14. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005; 106: 1590-1600. (Pubitemid 41208570)
15. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265: 1573-1577.
16. Metcalf D. Loss of PU1: one of the many roads to myeloid leukemia. Cell Cycle 2006; 5: 673-674.
17. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU1. Nat Genet 2004; 36: 624-630. (Pubitemid 38715991)
18. Yeamans C, Wang D, Paz-Priel I, Torbett BE, Tenen DG, Friedman AD. C/EBPalpha binds and activates the PU1 distal enhancer to induce monocyte lineage commitment. Blood 2007; 110: 3136-3142. (Pubitemid 350106304)
19. Yoshida H, Ichikawa H, Tagata Y, Katsumoto T, Ohnishi K, Akao Y et al. PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU1-induced C/EBPepsilon expression in myeloid differentiation. Mol Cell Biol 2007; 27: 5819-5834. (Pubitemid 47257836)
20. Puccetti E, Zheng X, Brambilla D, Seshire A, Beissert T, Boehrer S et al. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARαl. Cancer Res 2005; 65: 6080-6088. (Pubitemid 40994392)
21. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535-3543. (Pubitemid 38525689)
22. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 2008; 122: 2744-2752. (Pubitemid 351631376)
23. Koyama N, Koschmieder S, Tyagi S, Nurnberger H, Wagner S, Bocker U et al. Differential effects of histone deacetylase inhibitors on interleukin-18 gene expression in myeloid cells. Biochem Biophys Res Commun 2002; 292: 937-943. (Pubitemid 34687295)
24. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M et al. The acute promyelocytic leukemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 1998; 16: 1945-1953. (Pubitemid 28200606)
25. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Lanfrancone L et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998; 58: 14-19. (Pubitemid 28027708)
26. Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC et al. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. Hum Gene Ther 1998; 9: 1561-1570. (Pubitemid 28382958)
27. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431. (Pubitemid 23244608)
28. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 1997; 17: 4859-4869. (Pubitemid 27318161)
29. Wang K, Wang P, Shi J, Zhu X, He M, Jia X et al. PML/RARαl targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010; 17: 186-197.
30. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 2009; 23: 2242-2247.
31. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82: 1858-1867. (Pubitemid 23278777)
32. Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343. (Pubitemid 24046695)
33. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13: 1073-1083. (Pubitemid 24074714)
34. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A et al. Role of promyelocytic leukemia (PML) stimulation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193: 1361-1371. (Pubitemid 32565965)
35. Mü ller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006; 107: 3330-3338.
36. Lodie TA, Savedra Jr R, Golenbock DT, Van Beveren CP, Maki RA, Fenton MJ. Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. J Immunol 1997; 158: 1848-1856. (Pubitemid 127469543)
37. Mao C, Ray-Gallet D, Tavitian A, Moreau-Gachelin F. Differential phosphorylations of Spi-B and Spi-1 transcription factors. Oncogene 1996; 12: 863-873. (Pubitemid 26072272)
38. Carey JO, Posekany KJ, deVente JE, Pettit GR, Ways DK. Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. Blood 1996; 87: 4316-4324. (Pubitemid 26152273)
39. Riccioni R, Saulle E, Militi S, Sposi NM, Gualtiero M, Mauro N et al. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+acute promyelocytic leukemia. Leukemia 2003; 17: 98-113. (Pubitemid 36175894)
40. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. Potential autoregulation of transcription factor PU1 by an upstream regulatory element. Mol Cell Biol 2005; 25: 2832-2845. (Pubitemid 40381644)
41. Sapi E, Flick MB, Tartaro K, Kim S, Rakhlin Y, Rodov S et al. Effect of alltrans-retinoic acid on c-fms proto-oncogene [colony-stimulating factor 1 (CSF-1) receptor] expression and CSF-1-induced invasion and anchorageindependent growth of human breast carcinoma cells. Cancer Res 1999; 59: 5578-5585. (Pubitemid 29526477)
42. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 2006; 38: 27-37. (Pubitemid 43011879)
43. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002; 100: 998-1007. (Pubitemid 34832629)
44. Metcalf D, Dakic A, Mifsud S, Di Rago L, Wu L, Nutt S. Inactivation of PU1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 1486-1491. (Pubitemid 43191192)
45. Dohner K, Tobis K, Bischof T, Hein S, Schlenk RF, Frohling S et al. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood 2003; 102: 3850; author reply 3850-3851.
46. Lamandin C, Sagot C, Roumier C, Lepelley P, De Botton S, Cosson A et al. Are PU1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 2002; 100: 4680-4681. (Pubitemid 35429718)
47. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2003; 101: 2074. (Pubitemid 36237622)
48. Walter MJ, Park JS, Ries RE, Lau SK, McLellan M, Jaeger S et al. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARαl. Proc Natl Acad Sci USA 2005; 102. (35): 12513-12518. (Pubitemid 41266390)
49. Azim AC, Wang X, Park GY, Sadikot RT, Cao H, Mathew B et al. NF-kappaB-inducing kinase regulates cyclooxygenase 2 gene expression in macrophages by phosphorylation of PU.1. J Immunol 2007; 179: 7868-7875.
50. Gross SA, Zheng JH, Le AT, Kerzic PJ, Irons RD. PU.1 phosphorylation correlates with hydroquinone-induced alterations in myeloid differentiation and cytokinedependent clonogenic response in human CD34(+) hematopoietic progenitor cells. Cell Biol Toxicol 2006; 22: 229-241. (Pubitemid 44050813)
51. Lloberas J, Soler C, Celada A. The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages. Immunol Today 1999; 20: 184-189. (Pubitemid 29172282)
52. Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 2003; 102: 3727-3736. (Pubitemid 37409394)
53. Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L et al. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 1992; 101: 773-784.